Showing results (161-170 of 335) with videos related to

Sort By:
Pageof 34
The Journal of Laboratory and Clinical Medicine|February 7, 2006
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasmaAmanda F Baker, Tomislav Dragovich, Wendy R Tate, et al.
BMC Cancer|July 15, 2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyPashtoon M Kasi, Daisuke Kotani, Michael Cecchini, et al.
Clinical Colorectal Cancer|May 27, 2008
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancerRamesh K Ramanathan, Georg A Bjarnason, Stephen Alan Bernard, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|August 5, 2017
18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancerRonald L Korn, Daniel D Von Hoff, Mitesh J Borad, et al.
Investigational New Drugs|March 10, 2006
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapyHitendra Patel, Ronald Stoller, Miklos Auber, et al.
Clinical Colorectal Cancer|December 17, 2005
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancerHoward Hochster, Erika Kettner, Hendrik Kroning, et al.
Frontiers in Pharmacology|February 2, 2013
Clonal evolution and therapeutic resistance in solid tumorsMichael T Barrett, Elizabeth Lenkiewicz, Lisa Evers, et al.
Molecular and Cellular Biochemistry|December 21, 2006
Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumorsK Rohini, J Mathivanan, P D Antony Herold Prabhu, et al.
Investigational New Drugs|March 23, 2011
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancerA B El-Khoueiry, R K Ramanathan, D Y Yang, et al.
American Journal of Clinical Oncology|March 24, 2012
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinomaDaruka Mahadevan, Pavani Chalasani, Diane Rensvold, et al.
Pageof 34